chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Started with sore arm, chills, tightness in my chest, fatigue, heart palpitations, hard time walking for 2 days. Took Alleve and Tylenol. Symptoms lessened and were gone in about 2-3 days. Developed shingles on 12/22/2021. Saw Teledoc for shingles. Received antiviral for shingles.
known PCR-confirmed diagnoses/ known SARS-CoV-2 infection between the 2-week and 6-month draws; known PCR-confirmed diagnoses/ known SARS-CoV-2 infection between the 2-week and 6-month draws; This is a literature report for the following literature source(s): (Privacy).  Authors sampled 130 NH residents and 95 HCWs 6 months after vaccination who had been previously evaluated 2 weeks following vaccination. Patients were studied from December 2020 to July 2021 from 4 NHs. The HCWs were workers at the NH buildings and medical center who all had access to the same vaccine at the same time as the NH residents. All participants received 2 doses of vaccine regardless of prior SARS-CoV-2 infection. Of 225 participants with available 6-month follow-up, 13 (6%) were excluded for presumed or known SARS-CoV-2 infection between the 2-week and 6-month draws. All of these participants were in buildings or workspaces with known outbreaks. Those with presumed infection had an increase in titer greater than 100% at 6 months from the 2 week post-vaccine level in at least 1 of the immune assays. Five participants had known PCR-confirmed diagnoses; the other presumed cases were clinically undetected. Subjects that have been excluded with documented or presumed infection in the 2 week to 6 month interval: 75-year-old male. Reason for exclusion: PCR +ve, Titer rise (Titer rise denotes an increase greater than 100% in either or all of anti-spike, anti-RBD or neutralization titers); Clinical: Symptomatic (Symptomatic denotes subjects with COVID-like symptoms).  A 75 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "known PCR-confirmed diagnoses/ known SARS-CoV-2 infection between the 2-week and 6-month draws". The patient underwent the following laboratory tests and procedures: antibody test: titer rise; blood immunoglobulin g: unknown results; fluorescent in situ hybridisation: unknown results; sars-cov-2 antibody test: titer rise; sars-cov-2 test: positive; unknown results.  No follow-up attempts are possible, information about batch number cannot be obtained.; Sender's Comments: Based on the information currently available, a lack of efficacy with BNT162B2 in this patient cannot be completely excluded,Linked Report(s) : US-PFIZER INC-202200314527 Same article/ drug/event and different patient
Palpitations, difficulty breathing, vomiting, felt throat was tight, lightheaded.
Experienced body ache; Headache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Experienced body ache) and HEADACHE (Headache) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002B21A and 015M20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma and Arthritis.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced PAIN (Experienced body ache) and HEADACHE (Headache). At the time of the report, PAIN (Experienced body ache) and HEADACHE (Headache) outcome was unknown.            The patient was reporting their experiences after receiving the second dose. After the 2nd dose they experienced body aches and headache. It was also reported that the patient had a history of arthritis & asthma.  No Concomitant product use was reported. No treatment information was provided.   This case was linked to MOD-2021-405684, MOD-2021-405717 (Patient Link).
Immediately after giving the second injection, PPV23 patient became flaccid, started crying and put head back. She turned cyanotic around mouth eyes and nose. Was brought directly to EMS where O2 was started (around 4:45pm) and epinephrine 01 MES of 1:1000 SQ.
Localized swelling 2 inches plus; Low grade temperature 99.8; Joint pain; Malaise; Headache; Patient reports symptoms 5/17-5/21; TYLENOL.
At 2 month visit pt was given ProQuad instead of Prevnar. Discovered at 4 month visit. No known side effect yet no fever, rash, irritability with immunizations.
Pt with palpitations and flu like symptoms x 1 day.  Abnormal EKG in office - possible inferior infarct/sinus tachycardia. Taken to ED for work-up
Fatigue, granulocytes, swollen lymph nodes, human transforming growth factor beta 1 (extremely high), nauseas.
The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify. Follow-up information has been received from the practice manager on 18-SEP-2018. This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided. On 17-JAN-2018, the patient was vaccinated with an improperly stored dose of GARDASIL 9 (strength and route were unknown) (lot# N021475 and expiration date 31-JAN-2020) for prophylaxis (Incorrect product storage). No adverse event was reported. The excursion temperature on 08-NOV-2017, 16-NOV-2017, 23-JAN-2018, 06-JUN-2018, 03-JUL-2018 and 14-AUG-2018 was 47 degree Celsius for maximize 15 hours. The excursion temperature on 07-DEC-2017 was 50 degree Celsius for maximize 8.75 hours. The call was not because of data logger. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001957: US-009507513-1810USA001958: US-009507513-1810USA001959: US-009507513-1809USA003709.
Information has been received from a physician concerning a pt who about 2 weeks ago, in 08/03, was vaccinated IM from a multidose vial with a 0.5mL dose of pneumococcal 23v polysaccharide vaccine. Subsequently the pt developed localized swelling around the injection site which was described as painful, ring-like cellulitis and a fever of 102 deg F. Subsequently after a week, the pt had a complete recovery and was in "good" condition. Medical attention was sought and the pt was placed on an antibiotic (unspecified) for the cellulitis. No further information was provided. No product quality complaint was involved. It was also reported that 5 other pt's were vaccinated with a dose of pneumococcal 23v polysaccharide vaccine and also developed cellulitis (WAES # 0309USA01722 through 0309USA01724, 0311USA002365 & 0311USA02366).  It was also noted that of the 6 total pt's 5 received a booster dose and one had the first vaccination with the pneumococcal 23v polysaccharide vaccine. Additional information has been requested.
Herpes zoster diagnosis in two-dose varicella vaccine recipient. Painful unilateral rash in one dermatome, left arm. Lasted less than four weeks. No antiviral prescribed.
itching and now this skin pattern where it is easy to bleed/Skin bleeding; larger pattern of bruising/bruising; itching; Skin patching/Skin disorder; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old male patient received BNT162b2 (BNT162B2), on 09Apr2021 as dose 2, single (Batch/Lot number: unknown) at the age of 60 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Batch/Lot number: EP6955), administration date: 19Mar2021, for COVID-19 Immunization, reaction(s): "itching all over the body after rash formed", "rash on left arm above his wrist on forearm". The following information was reported: SKIN HAEMORRHAGE (non-serious), outcome "unknown", described as "itching and now this skin pattern where it is easy to bleed/Skin bleeding"; CONTUSION (non-serious), outcome "unknown", described as "larger pattern of bruising/bruising"; PRURITUS (non-serious), outcome "not recovered", described as "itching"; SKIN DISORDER (non-serious), outcome "unknown", described as "Skin patching/Skin disorder". The events "itching and now this skin pattern where it is easy to bleed/skin bleeding", "larger pattern of bruising/bruising" and "itching" required physician office visit. Clinical course: After second dose patient had itching which was probably to the top level of boosters that he had and where he was supposed to be and the condition of itching had increased dramatically and he had the skin condition to his forearms and it accelerated enough that it looks like if you were on a blood thinner where you had those kind of skin necrosis only he was not on a blood thinner. Pateint was seeing a dermatologist. The itching increased dramatically and he did not know when it began to increase dramatically but guesses it was when he first noticed it was just there and did not notice it being increased but noticed as of late there was a larger pattern of bruising, bleeding and patching that was bruised.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300290360 same patient/drug, different dose/events (Dose 4);US-PFIZER INC-202300290361 same patient/drug, different dose/events (Dose 5);US-PFIZER INC-202300290359 same patient/drug, different dose/events (Dose 3);US-PFIZER INC-2021412848 same patient/drug, different dose/events (Dose 1);
My father was given dose 1 and dose 2 of the covid 19 vaccine on 2/17/2021 against the POA's wishes. He was incoherent, looking up at the ceiling like he was close to death, he couldn't move his mouth, his arms are stiff and his body is still, he couldn't blink, he is not like himself. now his food is pureed and he can't chew, he's in a diaper full time now. to an adverse event report of parents received both doses of the vaccines on 2/17/21 and father is now bedridden an in diapers. He looks like he's had a major stroke
This morning noticed long strip of a rash on both arms on both side. Lethargy, dizziness, weakness, rapid heart beat.
Pt states after receiving HBV #1, he experienced "swelling of neck glands, abdomen pain, lungs shurting, nausea, shoulder, back, arm pain, weakness and blacks spots half dollar size(bruiselike) times 3 on legs, states  condition lasted times 2 to 3 days.
meningitis; Severe headache; Back pain; Inflammation; This case was reported by a physician via call center representative and described the occurrence of meningitis in a 44-year-old patient who received HAB (Twinrix) for prophylaxis.   On an unknown date, the patient received Twinrix at an unknown dose. On an unknown date, 1 day after receiving Twinrix, the patient experienced meningitis (serious criteria GSK medically significant), headache, back pain and inflammation. On an unknown date, the outcome of the meningitis, headache, back pain and inflammation were unknown.   The reporter considered the meningitis, headache, back pain and inflammation to be possibly related to Twinrix.  Additional details were reported as follows: The healthcare professional reported that he thought a bad batch of Twinrix gave his patient meningitis. The day after vaccination with Twinrix, the patient had severe headache and back pain. On an unknown date, the patient had nuclear magnetic resonance imaging (MRI) and lumbar puncture both showed evidence of inflammation, but all tests for viral, fungal and bacterial meningitis have been negative.      Lab Comments: On an unknown date, the patient had nuclear magnetic resonance imaging (MRI) and lumbar puncture both showed evidence of inflammation, but all tests for viral, fungal and bacterial meningitis have been negative.
This spontaneous report as received from a pharmacist refers to a newborn female patient of unknown age. On 20-OCT-2012 20:41, the patient was vaccinated with RECOMBIVAX HB that had been exposed to temperatures below 32F for 6 hours. During that 6 hour time period, the vaccine was exposed to 28.8F for 1.5 hours. Administration route was not reported. Two lot# were involved and the lot# were reported as: 0294AE, expiry date on 06-SEP-2014; and 0385AE, expiry date on 08-NOV-2014. It was unspecified which lot# the patient was administered. The outcome of event was unknown. It was unspecified if the patient sought medical attention. This is one of several reports received from the same source. Additional information has been requested.
On 11/15/2002 patient was brought in for exam. On 11/14/2002 she seemed to become more fussy and broke out in a brillant rash, likey atypical measles reaction to the first MMR vaccine. Follow up in next couple of days if not improving, otherwise supportive care and observation and administer Tylenol prn.
Hospitalization: 8/30/2022- ADMITTED, 9/6/2022- DISCHARGED. Presentation to the ED: congestion and a nonproductive cough and fever. She had a temperature of a 103° F on admission and was saturating at 93% on room air. COVID-19 + date: 8/30/22. Treatment: steroids, Remdesivir and increased O2 supply. Discharge to: SNF, (Skilled Nursing Facility).
The next morning after getting the shot, I woke up with pain on my right arm, the arm was red and swollen, my arm has a hard ball about the size of a golf ball, chills, headache and fatigue.
The day after receiving the COVID19 shot (upper left arm), I experienced swelling with a dull, insistent pain that seemingly moves down the back of my arm to my elbow and forearm and will occasionally cause the back of my hand and fingers to tingle or go numb.  While the swelling went down within 3 days, the uncomfortable pains have persisted and somewhat worsened.  I occasionally will feel a slight pain in my chest, which made me initially think it was due to my HBP, but my pressure was normal and I have taken my pills during this time.
Headache, NauseaVomiting,  fatigue  Narrative: Per patient report: "I was absent the whole day yesterday [3/17]  due to having an adverse reaction to the 2nd dose of my COVID19 vaccine. My symptoms included headache, nausea, and extreme fatigue."
RNs responded to patient honking horn in parking lot during waiting period. Father honked horn because patient seemed lightheaded. Patient c/o lightheadedness, chest tightness. Felt like it was anxiety driven. Vitals WNL, monitored for about 15 minutes and patient sent home. Patient did not want to follow up at hospital but was encouraged to go to ER if chest tightness came back or symptoms worsened. Pt verbalized understanding and was confident with the plan.
Received the anthrax vaccine (AVA) 10 weeks ago. Since then he has had ongoing tendonitis in his left shoulder near the site. The area began to be uncommonly painful 1-2 hours after the injection and has awakened him from sleep.
Around 10:00p.m. I was going to bed, when removing my clothes I begin shaking out of control, got dizzy /bad headache, then the chills. Had my son take me to the E.R. Was in the hospital for 3 hours also had fever with a very sore arm.  Gave me a shot of Benadryl and med. to bring down fever.  Since fever would not come down started IV. Went home was sick for 1 1/2 days. Toke Tylenol then 4 hours later Motrin to bring fever down and Lortab for pain.
Had to stay in bed for two days; Chills; Mixed Pfizer's and Moderna's vaccines; This spontaneous case was reported by a consumer and describes the occurrence of BED REST (Had to stay in bed for two days), CHILLS (Chills) and INTERCHANGE OF VACCINE PRODUCTS (Mixed Pfizer's and Moderna's vaccines) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 05-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient received first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient experienced BED REST (Had to stay in bed for two days), CHILLS (Chills) and INTERCHANGE OF VACCINE PRODUCTS (Mixed Pfizer's and Moderna's vaccines). At the time of the report, BED REST (Had to stay in bed for two days), CHILLS (Chills) and INTERCHANGE OF VACCINE PRODUCTS (Mixed Pfizer's and Moderna's vaccines) outcome was unknown.            No relevant concomitant medications were reported. No treatment information was provided.
Patient fainted following receiving the vaccine. 911 was called. After some time, patient eventually regained consciousness
Breast ultrasound showed inflammation of the left armpit lymph nodes. A second defined ultrasound was done confirming the result.  TX; repeat ultrasound in 6 months to confirm reaction to the C/19 vaccine
3" X 3.5" area of redness directly under injection site on left deltoid area of arm.
Due to reconstitution error patient was given less than half of required dosage. Patient was notified and returned to clinic to receive the appropriate dose the same day.
Information has been received from a doctor of pharmacy concerning a pediatric male with an allergy to gelatin, who was administered , on an unspecified date, a 1-10 dilution dose of measles virus vaccine live +mumps virus vaccine live+ rubella virus vaccine. Subsequently the patient "reacted violently" to the vaccine. Unspecified medical attention was sought. The patient's outcome was not reported. Additional information has been requested.
Lymph nodes under arm were swollen/ lymph nodes went down, the bursa area of shoulder; Shoulder became swollen; Shoulder extremely painful; Limited mobility; Swollen muscle in my shoulder; This is a spontaneous report from a contactable consumer (patient). A 32-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0187) via an unspecified route of administration in the right arm on 29Aug2021 at 07:50 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The patient's medical history was reported as none. The patient's concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On an unspecified date in 2021 (reported as 48-72 hours after receiving first dose), the patient had a swollen muscle on her shoulder. On 31Aug2021, 48 hours after the injection, the patient's lymph nodes under the arm were swollen and the patient knew it was normal. However after, swelling in the lymph nodes went down, the bursa area of her shoulder became swollen and extremely painful, resulted in limited mobility. This pain had persisted from the original date of injection. Therapeutic measures were taken as a result of event shoulder extremely painful which included treatment with naproxen sodium (ALEVE) from an unknown date to alleviate the pain at that moment. No treatment was received for the events axillary lymph nodes enlarged, joint swelling and mobility decreased. The swelling had not gone down and the pain has not subsided. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Vaccination facility type was Doctor's office/Urgent care. Vaccine was not administered at military facility. The clinical outcome of the events lymph nodes under arm were swollen/ lymph nodes went down, the bursa area of shoulder, shoulder became swollen, shoulder extremely painful and limited mobility were not recovered at the time of this report and the outcome of the event swollen muscle in her shoulder was unknown. Seriousness criteria of the event swollen muscle in her shoulder was reported as persistent/significant disability/Incapacity. The patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0187) via an unspecified route of administration in the right arm on 21Sep2021 at 09:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. The clinical course was reported as follows: 48-72 hours after receiving first dose I have had a swollen muscle in my shoulder and limited mobility. I have not gone to the hospital as I am uninsured and can not afford it.  Follow-up attempts are completed. No further information is expected.  Follow-up (12Oct2021): Follow-up attempts are completed. No further information is expected.
Patient's wife reported to the pharmacy that patient had recently had his annual influenza vaccination at his PCP's office. Patient is also on warfarin anticoagulation therapy, as well as undergoing an unknown chemotherapy regimen. Patient's wife reported the patient's entire arm where immunization was given was black and blue, including the underside of the arm. The patient reported the event to his PCP and Oncologist. The patient's INR was taken and found to be elevated, but that information was not provided. Patient normally takes 5-7mg warfarin daily, but was instructed to hold warfarin therapy until his INR was back into therapeutic range. It is unknown what other medications the patient is currently taking including chemotherapy drugs-, or if there were other factors affecting the patient's INR value. The patient was not hospitalized, and has recovered without further incident.
Patient began to vomit several times within 1 hour of receiving vaccine. Also, skin on face was blotchy.
Headache, NauseaVomiting, nausea without vomiting. headache Narrative:  c/o headache and nausea without vomiting 20 min. after 2nd dose vaccine. Took her own Tylenol (2) and was given water and juice to drink. 1215 initial 180/81, 71, 18, O2 sat 100% room air. @ 1230 136/75, 65, % O2 sat. Denied anymore nausea and headache was subsiding. Refused any snacks at this time. No SOB or dizziness noted.
Initial unsolicited report received from a pharmacist on 16-Oct-2017. This case involves 62-year-old male patient was vaccinated with 0.5ml dose of FLUZONE QIV once via intramuscular route in left deltoid, batch number: UI839AA (expiry date, dose in series were not reported) on 09-Sep-2017. Patient's medical history and concomitant medications were not reported. On an unknown date, following the vaccination, the patient experienced pain in his left shoulder with shooting pains with movement. The patient was demanding compensation. Lab data and corrective treatment were not reported. Event outcome was not recovered at the time of reporting. List of documents held by sender: none.
Short term- one week of orthostatic- 2 days specifically of not able to stand with our feeling like I was going to pass out.  Fever, tired, severe weakness, cold like symptoms. Long term- clavicular node and fatty node above left shoulder.  No other long term affects.